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Gut microbes play a key role in colorectal carcinogenesis, yet reaching a consensus on microbial
signatures remains a challenge. This is in part due to a reliance on mean value estimates. We
present an extreme value analysis for overcoming these limitations. By characterizing a power
law fit to the relative abundances of microbes, we capture the same microbial signatures as more
complex meta-analyses. Importantly, we show that our method is robust to the variations inherent
in microbial community profiling and point to future directions for developing sensitive, reliable
analytical methods.
PACS numbers: 87.19.xj, 87.23.Cc, 89.75.Da
Colorectal cancer (CRC) is the third most commonly
diagnosed cancer in the United States [1], resulting in
an estimated 50,000 deaths annually [2]. Development of
sporadic, i.e., non-hereditary, CRC is a complex process
typically defined by the adenoma-carcinoma sequence,
where there is first a transition from a normal colon ep-
ithelium to an adenomatous growth followed by a tran-
sition to a cancerous tumor [3]. Recently, evidence has
been mounting that alterations in the gut microbiome–
the approximately 100 trillion microbes residing in the
gut–play a crucial role in this transition from normal ep-
ithelium to cancerous tumor [4–6].
Profiling the taxonomic composition of the gut micro-
biome has been made possible due to recent advances in
16S rRNA sequencing, a technique that quantitatively
sequences hypervariable regions of the microbial rRNA
present in a sample and assigns taxonomy accordingly
[7, 8]. The microbial profiles of healthy subjects can then
be compared to the profiles of subjects with CRC. Specif-
ically, one common approach is to identify taxa that are
enriched in CRC subjects, then narrow down the list of
microbes that potentially drive CRC progression. This
may be sound in principle, but results are difficult to
interpret in practice when inconsistencies arise between
different studies [5, 9]. For instance, oral pathogen Pep-
tostreptococcus stomatis is often considered a known as-
sociate of CRC, with several studies having corroborated
these results [10–16]. Meanwhile, other studies show a
very weak [4] or even no association at all [5, 17–20]. At
the same time, these studies often find a number of other
possible signatures; thus, instead of clarifying the mi-
crobial drivers, these studies create additional confusion.
Recent meta-analyses systematically analyze previously
published 16S gene sequence data in an effort to iden-
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tify consistent signatures. However, these results only
confirm a limited number of species, and even highlight
that the majority of results from individual studies do
not agree [9, 16].
One commonly proposed reason for the inconsistencies
between studies is the existence of multiple mechanisms
by which microbes can promote CRC [5, 9, 18, 19]. The
result is that CRC drivers in one case may be uninvolved
in another, with even the few confirmed CRC signatures
displaying enrichment in, at most, a subset of cancerous
stool or tumor biopsy samples [9, 16–21]. Typical analy-
ses used to find these signatures rely on either the mean
or a rank ordering of taxa abundances and therefore can-
not reliably detect trends that only occur in a subset of
samples. In other words, these measures only detect gen-
eral and unidirectional shifts when, in fact, microbial ef-
fects are neither general nor linear. Further exacerbating
these issues, mean value estimates often assume symmet-
rical Gaussian [22] or zero-inflated Poisson distributions
[23, 24], which do not reflect real microbial distributions.
The field is in crucial need of reliable analysis methods
to parse out the signal from the noise.
In this study, we make use of extremal distributions as
a more sensitive and consistent means of identifying the
major microbial signatures associated with CRC progres-
sion. In doing so, we show that the relative abundance
distributions of putatively causative taxa follow a power
law whose tail, i.e. extreme values, differs between nor-
mal, adenoma, and CRC samples. We use a permuta-
tion test with extreme value test statistics to quantify
the differences in these asymmetrical distributions. We
show our extremal analysis to be robust by replicating
our findings in a separate, European cohort [11], also cor-
roborating the results of recent meta-analyses [9, 16, 25].
Employing a power law distribution to understand the
role of potential microbial culprits in CRC progression
will motivate, guide, and simplify future development of
analytical methods for microbial data.
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2A power-law-like distribution of microbial relative
abundances should not, in fact, be surprising. Obser-
vations of power laws are prevalent in nearly every field,
and reflect the universal importance of extreme events
across fields ranging from economics to ecology, describ-
ing events from wealth distribution in the US to wildfire
sizes [26]. Even just within the field of physics, power
law behaviors have received special attention; complex
social networks [27], avalanches [28], scientific citations
[29], and football goals [30] have all been characterized
to follow power laws. While we cannot claim a power law
distribution in our own work, understanding the charac-
teristics of power laws can nonetheless guide the analy-
sis of power-law-like data and reveal important insights.
For example, one insight gained is that the extreme val-
ues comprising the heavy tail of power laws are often
the most influential and informative to study [31, 32]. A
Gaussian approximation of a power law tail would un-
derestimate the extreme values, thereby underestimating
the mean. This insight deems approaches based on mean
values less appropriate and calls for extreme value anal-
ysis (EVA).
We examine the fecal microbiota of subjects who are
healthy (n = 486), have adenomas (n = 233), or have
CRC (n = 17) by using 16S rRNA gene sequences from
Hale et al. [6]. The relative abundance of each taxon
commonly cited in the field was determined for all sam-
ples at the genus level, the smallest taxonomic category
able to be identified accurately. Average sequence read
count was 6219, and samples with fewer than 2000 reads
were removed as done in the original analysis by Hale
et al. [6]. Removing these samples protects against the
sensitivity to sequencing depth variations that relative
abundances at the lower limit face.
While the relative abundances of high-abundance mi-
crobes show a distribution more similar to a symmetrical
Gaussian distribution, low-abundance microbes display a
highly right-skewed distribution with a heavy tail. Typi-
cal examples of genera displaying these two types of dis-
tributions are shown in Fig. 1.
As shown in Fig. 2, the right-skewed distributions do,
in fact, approximate power laws. However, it should
be noted that power laws are characterized by extreme
behavior that extends to infinity, while relative abun-
dances are bound by 1. In this study we only consider
low-abundance genera with a mean relative abundance
of less than 0.005. This left us with 11 out of the 18
total taxa characterized [45] (Akkermansia, Bifidobac-
terium, Bilophila, Desulfovibrio, Epulopiscium, Fusobac-
terium, Lachnobacterium, Parvimonas, Peptostreptococ-
cus, Pseudomonas, and Streptococcus).
Upon closer inspection, the length of the power law
tail appears to differ according to disease status (data
not shown). We therefore propose that the power law
tails, i.e. extreme values, of CRC drivers are the val-
ues that differ between the normal, adenoma, and can-
cer stages of CRC progression. In order to assess this,
we employ extreme value analysis to quantify these dif-
FIG. 1: Relative abundance distributions of typical high-
abundance (Coprococcus) and low-abundance (Desulfovibrio)
microbes. The former is more Gaussian, while the latter is
heavily right-skewed.
ferences. Examining data from subjects at each stage
of the adenoma-carcinoma sequence can then distinguish
a microbe’s role in the various stages of carcinogenesis
[33]. For example, a microbe that exhibits depletion of
extreme values in normal samples but enrichment in ade-
noma samples would indicate a role in the early transition
to cancer, whereas a microbe that exhibits only an en-
richment in cancer samples would suggest a later effect.
In order to focus our analysis on extreme rather than
mean values, we perform a permutation test on an ex-
treme value measure to determine the role of microbial
taxa in CRC etiology. An advantage of using a permu-
tation test is that it is non-parametric, hence we do not
make faulty assumptions about distributional symmetry.
We can also choose any extreme value measure to test.
One such example is a simple maximum [34]; however,
this statistic is overly dependent on a single data point,
making it sensitive to random fluctuations and technical
artifacts. Instead, we found averaging over the x greatest
values (maxx) to be a more reliable measure of extreme
behavior. This statistic represents the maximum while
eliminating noise, and it defines the ”leading edge” of
the abundance values.
While we utilize the previously mentioned insight
about power law tails to focus our analysis on extreme
values, importantly, our non-parametric approach does
not rely on estimates of power law parameters, or even
a rigorous claim that the relative abundances follow a
strictly power law distribution.
We test this approach for different values of x (max3,
max5, and max7) and find nearly identical results de-
spite different sample sizes in each group (see Appendix
A). These results indicate that these defined sizes of the
leading edge are sufficient to produce reliable results, in-
dependent of sample size. We carry on by performing the
permutation test using only the max5 test statistic.
3FIG. 2: Log-log transformations reveal that the 11 genera examined approximate power law relative abundance distributions.
By comparing the group max5 values generated from
the 10,000 random permutations of normal, adenoma,
and cancer to the observed max5 values, we are able to
conclude whether the observed extreme values in each
group are higher or lower than expected. Note that
the calculated expectations for extreme values depend on
sample size, as larger samples are more likely to include
more extreme values than smaller samples. Correspond-
ingly, cohorts with different sample sizes between groups
lead to different expectations for extreme values in each
group as well.
When applied to Desulfovibrio, we find that the max5
statistic is lower than expected in the normal group and
higher than expected in the adenoma group, indicating a
role for this genus in the transition from normal to ade-
noma (Fig. 3). Applying these methods to the 10 other
taxa studied, results are also found for Fusobacterium
and Peptostreptococcus, both enriched in cancer (Fig. 4).
As additional confirmation, we implement an ex-
ploratory parametric EVA method that explicitly applies
the power law model to estimate an expected number of
extreme values (see Appendix B for detailed methods).
Briefly, we normalize a power law fit to the microbial
abundances and estimate the number of expected ex-
treme values above a defined critical relative abundance
value, which we then compare to the observed number of
extreme values. Our results match the permutation test
results for Peptostreptococcus (p = 0 in the normal group,
p = .015 in the adenoma group, p = .009 in the cancer
group) and are non-significant but trending in the same
direction for Desulfovibrio (p = .065 in the normal group)
and Fusobacterium (p = .141 in the normal group). The
uncertainty in the power law parameters lowers the de-
tected significance, but overall these results strengthen
our findings based on the permutation test. Improving
the power law model and its corresponding PDF would
further enhance the applicability of this approach.
Finally, we examine if our results can be generalized
to other studies. Inconsistencies between different stud-
ies arise due to many different factors including batch
effects [35, 36] and sequencing biases from collection [37–
39], primer design [40], PCR conditions [41], and lab-
to-lab variation [37, 42]. However, an advantage of our
approach is that the overall distributional characteristics
should remain relatively stable. We therefore expect our
extreme value approach, which makes assessments based
off the observed distribution, to be more robust to these
variations.
In order to test this, we replicate our results in a sep-
arate European cohort (61 normal, 42 adenoma, and 53
cancer) obtained from Zeller et al. [11] that used dif-
ferent collection methods, primer design, and sequencing
4FIG. 3: Permutation distributions of the average of maxi-
mum 5 relative abundances test statistic (max5) for Desul-
fovibrio. 10,000 random permutations were generated to pro-
duce expected distributions of the max5 values in each group:
normal, adenoma, and cancer. Lines indicate actually ob-
served max5 values. An observed value near the middle of the
expected distribution would indicate an expected result, while
one near the ends would indicate significance. Consequently,
observed max5 is significantly lower than expected in normal
and higher than expected in adenoma. In order to visualize
the significance and direction of results, barcharts are shown
below each histogram, with x-axis representing left-sided p-
values ranging from 0 to 1. One-sided p-values (whichever is
smaller) are also labeled on the left of the barcharts (bold p-
values < .05). Therefore, a significantly lower than expected
result is indicated by a small shaded region, while a signif-
icantly higher than expected result is indicated by a large
shaded region.
platforms processed in a different lab [46]. The same 11
genera are tested as previously described using the per-
mutation test. Indeed, results for all of the signatures
found in Hale et al. (Desulfovibrio, Fusobacterium, and
Peptostreptococcus) are confirmed; Desulfovibrio is found
to be depleted in normal, and Fusobacterium and Pep-
tostreptococcus enriched in cancer but depleted in normal
(Fig. 5).
It is worth addressing the two results that differ be-
tween the American and European cohort. Specifically,
FIG. 4: Taxa from Hale et al. with significantly different
than expected extreme values at each stage of CRC progres-
sion. One-sided p-values are shown from the permutation test
using the max5 test statistic. Note that results fBold p-values
< .05
the European cohort results show Akkermansia and Por-
phyromonas to have significant positive associations with
cancer (Fig. 5). However, these appear to be the result
of differences in study design. For Akkermansia, cohort
size of the cancer group was larger in the European co-
hort, making significance easier to assess in the adenoma
to cancer transition. Porphyromonas was completely un-
detected by Hale et al., making it methodologically im-
possible to assess computationally. In addition to study
design-based limitations, it should also be noted that the
p-values reported here are calculated without multiple
hypothesis correction. However, the number of genera
considered is relatively small, and our several replications
of the results provide an additional level of stringency.
Overall, our results are very consistent, demonstrat-
ing the robustness of EVA. It is important to note that
our relatively simple permutation model performed on
a single dataset captures many of the same signatures
that otherwise have only been confirmed by more com-
plex meta-analyses, most of which show agreement on
the importance of Fusobacterium and Peptostreptococcus
[9, 16, 25]. The match in results is a testament to the
equal, if not greater, sensitivity and reliability of EVA
compared to other methods. Moreover, EVA identified
Desulfovibrio and Akkermansia to be significantly asso-
ciated with the transition to adenoma and cancer stage,
respectively, a result that went undetected in the original
analysis by Zeller et al. [11].
Nonetheless, EVA has some limitations. By defini-
tion, EVA requires capturing rare events and thus per-
forms best with a large number of samples. Fortunately,
large-scale microbiome studies are becoming increasingly
common [43, 44] as high-throughput sequencing becomes
more accessible. In this context, EVA takes advantage
of this progress while being less influenced by the vari-
ations inherent in microbial community profiling than
mean value analyses.
Future work may shift the paradigm of analytical
methods for 16S rRNA sequencing data. Already, we
have demonstrated the power of EVA to generate con-
5FIG. 5: Replication of results in separate, European cohort (Zeller et al.) and comparison to previous Hale et al. results.
Log-log transformations and permutation distributions for Desulfovibrio using the max5 statistic are shown as a representative
example. One-sided p-values from the permutation test are visualized for both Zeller et al. and Hale et al. to compare.
Note that results support consistent conclusions in both cohorts for Desulfovibrio, Fusobacterium, and Peptostreptococcus.
Porphyromonas was undetected in Hale et al. Bold p-values < .05
sistent results despite the multiple different mechanisms
by which the microbiome drives CRC. Understanding
that relative abundances of potential CRC drivers follow
the ubiquitous power law distribution provides a guiding
framework for developing future analytical tools. The
characteristic lack of a finite mean exhibited by power
laws explains the challenges of mean value analyses, mo-
tivating a shift towards EVA. Advancements in EVA,
guided by this realization, will result in a clearer, sim-
pler, and more accurate way to understand the role that
key gut microbes play in the development and progres-
sion of CRC.
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Appendix A: Sensitivity of Extremal Averages
One method of measuring extreme values is to exam-
ine sample maxima; however, a single maximum value is
often sensitive to random fluctuations and technical arti-
facts. Averaging a number of maximum values remedies
this problem. Here, we considered using the average of
3 (max3), 5 (max5), and 7 (max7) maximum values in
order to derive the test statistic that is most suitable.
All three measures performed nearly identically (Fig. 6).
The index of dispersion was used as a quantitative mea-
sure of the differences between the test statistics,
D = σ2/µ (A1)
where σ2 is the variance and µ is the mean of the three
p-values for each group. Indeed, the resulting indices of
dispersion were very low, ranging from D = 0 to .014.
Appendix B: Parametric EVA Methods
The exploratory parametric EVA method first fits a
power law to the microbial abundance data, as in Fig. 2.
β0 and β1 from a linear fit to the log-log transformed
data of bin interval I are exponentiated to derive a crude
power law fit:
y = β0 + β1x, (B1)
f(x) = 10β0xβ1 (B2)
A cutoff point, or critical value, is then determined to
define the extreme values. A conditional inference tree
is used to find the critical value, and the average of 1000
bootstrap samples is taken. We can now derive the total
expected number of extreme values (E) from Eq. (B3),
using the integral of the power law from the critical value
to 1 (the maximum possible relative abundance):
∫ 1
c
f(x)dx =
10β0(1− cβ1+1)
β1 + 1
, (B3)
E =
∫ 1
c
f(x)dx
I
(B4)
The integral must be divided by bin interval I because
counts are discrete. The number of observed extreme
values in each group (normal, adenoma, and cancer) is
then compared to expected using a binomial test, where
x = observed counts, n = group sample size, and p = E/
total sample size.
8FIG. 6: Sensitivity analysis of permutation test statistic
using average of maximum 3 (max3), 5 (max5), and 7 (max7)
values. Analyses were conducted using data from Hale et al.
Bold p-values < .05
